Cardiovascular Diseases

Philip Adamson, M.D., M.Sc., details the relationship between cardiovascular manifestations and COVID-19.

Using AI and real-world data, investigators identify drugs that can be used to treat heart disease.

New study findings demonstrate patients with treatment-resistant hypertension rarely get tested for primary aldosteronism.

The panel supports an expanded indication but struggles to reach consensus on what an expanded label might look like.

The NDA submission comes following the results of a phase 3a trial.

Women have an increased risk of heart disease in the years leading up to menopause.

The idea that social factors affect health outcomes is not new, but new research suggests total number of social determinants of health is a valuable proxy for coronary heart disease risk.

Women are disproportionately affected by heart failure after heart attacks, according to a Canadian study.

While glucocorticoids are widely used to reduce inflammation in patients with many inflammatory diseases, doctors don’t know whether a low to moderate glucocorticoid dose increases cardiovascular risk.

FDA approves several drugs to treat rare conditions in both cancer and metabolic diseases.

Entresto (sacubitril-valsartan) didn’t get a lot of love from payers after it was approved in 2015 because of its expense and the crowded armamentarium for heart failure. But Entresto has since made its way into guidelines for reduced ejection fraction heart failure, sometimes called systolic heart failure.

Updates from the American Heart Association Scientific Sessions.

A Cleveland Clinic scientist stopped short of saying doctors should take patients off Vascepa, but he said he has questions due to the lack of a "neutral comparator."

Overall, the Polycap polypill (simvastatin, atenolol, hydrochlorothiazide, ramipril) falls well short of the high expectations for the polypill approach to cardiovascular disease risk reduction.

The findings are the first in a series of six studies involving a registry supported by drug makers in the diabetes, cardiovascular, and heart failure space.

The first in a new class of drugs that targets the cardiac muscle is especially effective in patients with the most serious heart failure.

Biogen's controversial therapy hits headwinds with panel; stroke indication for Brilinta.

FDA approves new uses for companion diagnostics, while Janssen seeks a new indication for Xarelto.

The legislation follows an investigation that highlighted how minorities experience much higher rates of lower limb amputation than whites.

Flu increases the risk of heart attack, especially among people with diabetes and atherosclerotic cardiovascular disease (ASCVD). COVID-19 and the possibility of co-infection makes getting vaccinated against the flu particularly important this year.

Sodium glucose co-transporter 2 (SGLT2) inhibitors have already remade the diabetes drug market. Now competition for new cardiac and renal indications is heating up among three of the main drugs in the class: Janssen’s Invokana (canagliflozin), AstraZeneca’s Farxiga (dapagliflozin), and Eli Lilly/Boehringer-Ingelheim’s Jardiance (empagliflozin).

An immunotherapy combination gets a third thoracic indication; another potential indication for an SGLT2 inhibitor.

Patient navigators, following an algorithm and using telephone calls to contact patients, improved ACE inhibitor and beta blocker usage among heart failure patients.

The 2020 meeting, presented in a virtual format from its original host city of Amsterdam, The Netherlands, had lots of important science and a record number of viewers.